Chapter 16 – Investigational Therapies for Psoriasis

[1]  A. Gottlieb,et al.  Tildrakizumab (MK‐3222), an anti‐interleukin‐23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo‐controlled trial , 2015, The British journal of dermatology.

[2]  B. Strober,et al.  Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. , 2015, The New England journal of medicine.

[3]  S. Chimenti,et al.  Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial , 2015, The Lancet.

[4]  K. Reich,et al.  A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. , 2015, The New England journal of medicine.

[5]  L. Ferris,et al.  Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. , 2015, The Journal of allergy and clinical immunology.

[6]  A. Menter,et al.  Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. , 2014, Journal of the American Academy of Dermatology.

[7]  M. Genovese,et al.  Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. , 2014, The New England journal of medicine.

[8]  Y. Wasfi,et al.  Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. , 2014, The Journal of allergy and clinical immunology.

[9]  A. Menter,et al.  Tofacitinib (CP‐690,550), an oral Janus kinase inhibitor, improves patient‐reported outcomes in a phase 2b, randomized, double‐blind, placebo‐controlled study in patients with moderate‐to‐severe psoriasis , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

[10]  B. Strober,et al.  Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment , 2013, The British journal of dermatology.

[11]  D. M. van der Heijde,et al.  Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA) , 2013, Annals of the rheumatic diseases.

[12]  B. Strober,et al.  Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo‐controlled dose‐ranging study , 2012, The British journal of dermatology.

[13]  A. Gottlieb,et al.  Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab′ certolizumab pegol: results of a phase II randomized, placebo‐controlled trial with a re‐treatment extension , 2012, The British journal of dermatology.

[14]  A. Kimball,et al.  Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) , 2008, The Lancet.

[15]  Kathleen M. Smith,et al.  IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2–dependent mechanisms with implications for psoriasis pathogenesis , 2006, The Journal of experimental medicine.

[16]  M. Dhodapkar,et al.  Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis Vulgaris , 2004, The Journal of experimental medicine.

[17]  H. Nakagawa,et al.  Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study. , 2016, Journal of dermatological science.